312 related articles for article (PubMed ID: 17989143)
21. Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats.
Boesen EI; Williams DL; Pollock JS; Pollock DM
Clin Exp Pharmacol Physiol; 2010 Oct; 37(10):1016-22. PubMed ID: 20626757
[TBL] [Abstract][Full Text] [Related]
22. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.
Matsumura Y; Hashimoto N; Taira S; Kuro T; Kitano R; Ohkita M; Opgenorth TJ; Takaoka M
Hypertension; 1999 Feb; 33(2):759-65. PubMed ID: 10024341
[TBL] [Abstract][Full Text] [Related]
23. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
24. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus.
Venegas-Pont M; Manigrasso MB; Grifoni SC; LaMarca BB; Maric C; Racusen LC; Glover PH; Jones AV; Drummond HA; Ryan MJ
Hypertension; 2010 Oct; 56(4):643-9. PubMed ID: 20696988
[TBL] [Abstract][Full Text] [Related]
25. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats.
Jin L; Beswick RA; Yamamoto T; Palmer T; Taylor TA; Pollock JS; Pollock DM; Brands MW; Webb RC
J Physiol Pharmacol; 2006 Sep; 57(3):343-57. PubMed ID: 17033089
[TBL] [Abstract][Full Text] [Related]
26. Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection.
Newaz MA; Yousefipour Z; Hercule H; Truong L; Oyekan A
Clin Exp Hypertens; 2003 Aug; 25(6):335-47. PubMed ID: 12940471
[TBL] [Abstract][Full Text] [Related]
27. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Ma SK; Kim SW
Hypertens Res; 2010 Mar; 33(3):255-62. PubMed ID: 20057489
[TBL] [Abstract][Full Text] [Related]
28. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension.
Manhiani M; Quigley JE; Knight SF; Tasoobshirazi S; Moore T; Brands MW; Hammock BD; Imig JD
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F740-8. PubMed ID: 19553349
[TBL] [Abstract][Full Text] [Related]
29. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Pu Q; Amiri F; Gannon P; Schiffrin EL
J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
[TBL] [Abstract][Full Text] [Related]
30. Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats.
Giulumian AD; Pollock DM; Clarke N; Fuchs LC
Am J Physiol; 1998 Jun; 274(6):R1613-8. PubMed ID: 9608015
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of soluble guanylyl cyclase in the inner medulla of DOCA-salt hypertensive rats.
Taylor TA; Pollock JS; Pollock DM
Vascul Pharmacol; 2003 Oct; 40(3):155-60. PubMed ID: 13678647
[TBL] [Abstract][Full Text] [Related]
32. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
[TBL] [Abstract][Full Text] [Related]
33. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats.
Jadhav A; Torlakovic E; Ndisang JF
Am J Physiol Renal Physiol; 2009 Mar; 296(3):F521-34. PubMed ID: 19116243
[TBL] [Abstract][Full Text] [Related]
34. Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats.
Wang DS; Xie HH; Shen FM; Cai GJ; Su DF
Clin Exp Pharmacol Physiol; 2005 Jul; 32(7):545-52. PubMed ID: 16026514
[TBL] [Abstract][Full Text] [Related]
35. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response.
Beswick RA; Zhang H; Marable D; Catravas JD; Hill WD; Webb RC
Hypertension; 2001 Feb; 37(2 Pt 2):781-6. PubMed ID: 11230373
[TBL] [Abstract][Full Text] [Related]
36. Role of ET-1 receptor binding and [Ca(2+)](i) in contraction of coronary arteries from DOCA-salt hypertensive rats.
Giulumian AD; Molero MM; Reddy VB; Pollock JS; Pollock DM; Fuchs LC
Am J Physiol Heart Circ Physiol; 2002 May; 282(5):H1944-9. PubMed ID: 11959662
[TBL] [Abstract][Full Text] [Related]
37. ETA receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats.
Fujita K; Matsumura Y; Miyazaki Y; Hashimoto N; Takaoka M; Morimoto S
Life Sci; 1996; 58(1):PL1-7. PubMed ID: 8628104
[TBL] [Abstract][Full Text] [Related]
38. Antihypertensive effects of chicken extract against deoxycorticosterone acetate-salt-induced hypertension in rats.
Matsumura Y; Okui T; Ono H; Kiso Y; Tanaka T
Biol Pharm Bull; 2001 Oct; 24(10):1181-4. PubMed ID: 11642328
[TBL] [Abstract][Full Text] [Related]
39. Increased renal medullary endothelin-1 synthesis in prehypertensive DOCA- and salt-treated rats.
Hsieh TJ; Lin SR; Lee YJ; Shin SJ; Lai YH; Hsu CH; Tsai JH
Am J Physiol Renal Physiol; 2000 Jul; 279(1):F112-21. PubMed ID: 10894793
[TBL] [Abstract][Full Text] [Related]
40. NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension.
Li L; Watts SW; Banes AK; Galligan JJ; Fink GD; Chen AF
Hypertension; 2003 Sep; 42(3):316-21. PubMed ID: 12885792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
